Nandini Verma

Molecular Cell Biology Weizmann Institute of Science, Rehovot, Israel 
"Nandini Verma"
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Verma N, Müller AK, Kothari C, et al. (2020) Correction: Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. Cancer Research. 80: 362
Kedan A, Verma N, Saroha A, et al. (2018) PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein. Cell Death & Disease. 9: 985
Shin SY, Müller AK, Verma N, et al. (2018) Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer. Plos Computational Biology. 14: e1006192
Verma N, Müller AK, Kothari C, et al. (2016) Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis. Cancer Research
Verma N, Keinan O, Selitrennik M, et al. (2015) PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition. Nature Communications. 6: 6064
See more...